NeuroThera Labs Inc., a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd., announced that its collaborator Clearmind Medicine Inc. has filed a patent application in Hong Kong for a novel combination therapy designed to treat major depressive disorder. The therapy combines Clearmind's proprietary compound 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera.
The patent filing represents a significant step in developing what the companies describe as a non-hallucinogenic neuroplastogen option for depression. According to a World Health Organization article titled "Depressive Disorder (Depression)" published in August 2025, depression affects more than 332 million people globally. The companies suggest this MEAI-PEA combination could provide a more accessible, safer, and affordable alternative to existing antidepressants like Selective Serotonin Reuptake Inhibitors (SSRIs) and other conventional treatments.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on discovering and developing novel psychedelic-derived therapeutics. The company's intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. For further information about Clearmind, visit https://www.clearmindmedicine.com. NeuroThera Labs is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders through collaborations and innovative combinations.
The announcement contains forward-looking statements regarding the potential therapeutic benefits of the MEAI-PEA combination therapy, its potential advantages over existing antidepressants, and the presumed mechanism of action as a non-hallucinogenic neuroplastogen. These statements are subject to numerous risks and uncertainties, including the early stage of development, the risk that the therapy may not demonstrate anticipated safety or efficacy advantages, and the risk that the patent application may not result in a granted patent. Additional risks are described in the Company's public filings available on SEDAR+ at www.sedarplus.ca.
The development is important because it addresses a global health challenge affecting hundreds of millions of people. If successful, this therapy could expand treatment options for major depressive disorder, potentially offering a different mechanism of action compared to current standards of care. The collaboration between NeuroThera and Clearmind highlights the growing interest in novel neuroplastogen approaches to mental health conditions, moving beyond traditional pharmaceutical models. The patent application in Hong Kong represents an initial step in securing intellectual property protection for this innovative approach, which could have implications for treatment accessibility and cost in the future.
